Afficher la couverture 'Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC | Lencioni, Riccardo' en grand format
/5

0 avis

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Archive ouverte

Lencioni, Riccardo | Montal, Robert | Torres, Ferran | Park, Joong-Won | Decaens, Thomas | Raoul, Jean-Luc | Kudo, Masatoshi | Chang, Charissa | Ríos, José | Boige, Valérie | Assénat, Eric | Kang, Yoon-Koo | Lim, Ho-Yeong | Walters, Ian | Llovet, Josep

Edité par CCSD ; Elsevier -

International audience. The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate whether objective response by mRECIST accurately predicted overall survival (OS) in patients with advanced HCC treated with systemic targeted therapies and also to preliminarily assess this end-point as a potential surrogate of OS.

Consulter en ligne

Suggestions

Du même auteur

Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study

Archive ouverte | Kudo, Masatoshi | CCSD

International audience. Background:An unmet need exists for treatment of patients with advanced hepatocellular carcinoma (HCC) who progress on or are intolerant to sorafenib. A global randomized phase II trial (Clin...

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Archive ouverte | Zhu, Andrew | CCSD

International audience. Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hep...

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

Archive ouverte | Kudo, Masatoshi | CCSD

International audience. Background & aims: The albumin-bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (...

Chargement des enrichissements...